The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Nanoparticles with diameters of *100 nm (dnm) are used to target the tumor tissues which accumulate in tumor cells through the leaky tumor vasculature via the enhanced permeability and retention (EPR) effect (Maeda et al. 2000), a universal phenomenon in solid tumors (with some exceptions in the case of hypovascular t…”
MethodMultidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The MRP family proteins (MRP1-9) belong to the C group of the ABC transporters, which currently consists of 13 related members (ABCC1-13), that transport various organic anions (Borst et al. 2000; Toyoda et al. 2008) through conjugation with glutathione, glucuronide, glucose or sulfate; however, they can also be trans…”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Design considerations for tumour-targeted nanoparticles
Choi, H. S., Liu, W., Liu, F., Nasr, K., Misra, P., Bawendi, M. G., & Frangioni, J. V. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2009.314 · Cited by 754
Wang, R. B., Kuo, C. L., Lien, L. L., & Lien, E. J. (2003) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2003.00487.x · Cited by 225
Cited by
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Recent advances (2015–2016) in anticancer hybrids
Kerru, N., Singh, P., Koorbanally, N., Raj, R., & Kumar, V. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.033 · Cited by 295
Metadata
- Authors
- Kibria, G., Hatakeyama, H., & Harashima, H.
- Venue
- Archives of Pharmacal Research
- Published
- 2013-11-23
- Volume
- 37
- Issue
- 1
- Pages
- 4-15
- ISSN
- 0253-6269 (ISSN-L)
- 1976-3786
- OpenAlex
- W2032028642
- Cited by
- 171
- References
- 9
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.